Genmab A/S (GMAB)
35.31
+0.48
(+1.38%)
USD |
NASDAQ |
Sep 25, 14:13
Genmab Cash from Operations (TTM) : 891.90M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 891.90M |
| March 31, 2026 | 905.44M |
| December 31, 2025 | 1.190B |
| September 30, 2025 | 1.287B |
| June 30, 2025 | 1.047B |
| March 31, 2025 | 1.200B |
| December 31, 2024 | 1.133B |
| September 30, 2024 | 964.82M |
| June 30, 2024 | 967.89M |
| March 31, 2024 | 817.74M |
| December 31, 2023 | 1.064B |
| September 30, 2023 | 878.88M |
| June 30, 2023 | 854.47M |
| March 31, 2023 | 925.73M |
| December 31, 2022 | 547.90M |
| September 30, 2022 | 537.50M |
| June 30, 2022 | 354.42M |
| March 31, 2022 | 251.07M |
| December 31, 2021 | 354.49M |
| September 30, 2021 | 224.41M |
| June 30, 2021 | 899.69M |
| March 31, 2021 | 857.06M |
| December 31, 2020 | 988.35M |
| September 30, 2020 | 1.107B |
| June 30, 2020 | 389.37M |
| Date | Value |
|---|---|
| March 31, 2020 | 423.67M |
| December 31, 2019 | 197.59M |
| September 30, 2019 | 206.07M |
| June 30, 2019 | 187.89M |
| March 31, 2019 | 181.70M |
| December 31, 2018 | 161.16M |
| September 30, 2018 | 170.44M |
| June 30, 2018 | 151.59M |
| March 31, 2018 | 210.46M |
| December 31, 2017 | 241.65M |
| September 30, 2017 | 189.02M |
| June 30, 2017 | 206.55M |
| March 31, 2017 | 157.97M |
| December 31, 2016 | 48.91M |
| September 30, 2016 | 98.35M |
| June 30, 2016 | 88.44M |
| March 31, 2016 | 53.67M |
| December 31, 2015 | 46.59M |
| September 30, 2015 | 10.13M |
| June 30, 2015 | 6.342M |
| March 31, 2015 | 19.14M |
| December 31, 2014 | 23.76M |
| September 30, 2014 | 20.12M |
| June 30, 2014 | -5.409M |
| March 31, 2014 | -19.32M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| AbbVie, Inc. | 19.51B |
| Ascendis Pharma A/S | 405.71M |
| Zealand Pharma A/S | -241.46M |
| Bavarian Nordic A/S | 221.90M |
| Evaxion AS | -- |